Vascular Medicine Conference-CVC 2026

Novel antithrombotics are a new class of medications designed to prevent or treat thrombosis by targeting specific pathways in the coagulation cascade or platelet activation. This group includes direct oral anticoagulants (DOACs), factor Xa inhibitors, thrombin inhibitors, and innovative antiplatelet agents. They come with several benefits compared to traditional therapies, like predictable pharmacokinetics, fewer dietary restrictions, and less frequent monitoring.

These medications are utilized in various clinical situations, such as atrial fibrillation, venous thromboembolism, acute coronary syndromes, and post-stent management. Choosing the right therapy depends on individual patient factors, including renal function, bleeding risk, and any existing comorbidities. Ongoing research is actively looking into new targets and combination strategies to boost effectiveness, reduce complications, and enhance long-term cardiovascular outcomes.